The usual approach for myeloma patients who are not in a study is treatment with lenalidomide alone after stem cell transplant.
This study is being done to answer the following questions:
Patients in this study will either get lenalidomide alone after stem cell transplant or will get lenalidomide and daratumumab/rHuPH20. Both groups will get tested to see whether they have MRD (small amounts of multiple myeloma cells left after cancer is in remission). If they have MRD and their disease is responding to treatment, they will get treatment until their disease gets worse or their side effects are too great. If they do not have MRD and their disease is responding to treatment, they will be randomized to either STOP treatment or CONTINUE treatment until their disease gets worse or their side effects are too great.
This MRD test is approved by the FDA to test for low amounts of disease in myeloma patients. It is not FDA-approved for doctors to use to decide whether to stop maintenance therapy. One of the questions this study is asking is whether this test can be used to make that treatment decision.
Detailed eligibility will be reviewed when you contact the study team.